1. Home
  2. UPLD vs AKTX Comparison

UPLD vs AKTX Comparison

Compare UPLD & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Upland Software Inc.

UPLD

Upland Software Inc.

HOLD

Current Price

$5.02

Market Cap

17.3M

Sector

Technology

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$13.11

Market Cap

18.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UPLD
AKTX
Founded
2010
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.3M
18.2M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
UPLD
AKTX
Price
$5.02
$13.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$3.75
$33.50
AVG Volume (30 Days)
62.7K
92.3K
Earning Date
05-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
63.38
N/A
EPS
N/A
N/A
Revenue
$74,767,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.95
N/A
52 Week Low
$0.50
$0.12
52 Week High
$6.65
$29.32

Technical Indicators

Market Signals
Indicator
UPLD
AKTX
Relative Strength Index (RSI) 70.06 54.86
Support Level $0.62 $0.32
Resistance Level $5.60 $15.50
Average True Range (ATR) 0.39 1.88
MACD -0.07 0.17
Stochastic Oscillator 63.13 66.67

Price Performance

Historical Comparison
UPLD
AKTX

About UPLD Upland Software Inc.

Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels. Geographically, the company has operations in the U.S., United Kingdom and Canada, of which United States derives maximum revenue.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: